1
|
Rhee MK, Zakher M, Najac M, Arias H, Jo J, Gorham R, Moadel K. Comparing Intracanalicular and Topical Steroid Use in Patients Undergoing Pterygium Surgery. Eye Contact Lens 2024; 50:183-188. [PMID: 38305478 PMCID: PMC10953680 DOI: 10.1097/icl.0000000000001075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/07/2023] [Indexed: 02/03/2024]
Abstract
OBJECTIVE The study received funding from Ocular Therapeutix, Inc., Bedford, MA.We undertook this study to compare the efficacy of intracanalicular dexamethasone 0.4 mg with topical prednisolone acetate (PA) 1% in controlling postoperative pain and inflammation in patients undergoing pterygium surgery. METHODS This was an open-label, prospective, interventional, nonrandomized comparative trial. Thirty patients were assigned to one of the following groups: Group A [intracanalicular insert of 0.4 mg dexamethasone placed into upper and lower puncta during the procedure, followed by at postoperative month 1 visit institution of topical PA 1% twice daily × 2 weeks then once daily × 2 weeks] or Group B [nonintervention group with institution on postoperative day 1 topical PA 1% every 2 hours × 2 weeks then four times per day × 2 weeks then twice daily × 2 weeks then once daily × 2 weeks]. RESULTS Fifteen cases and 15 controls were enrolled. There was no statistical difference in patient-reported pain or satisfaction between the case and control groups at 1 day; 1 week; and 1, 3, and 6 months postoperatively. There was no significant difference in time to an ocular hyperemia score of 0 between the two groups. There was no difference in the rate of corneal reepithelialization and recurrence rate (two controls). Nine eyes had transient ocular hypertension (seven cases and two controls). CONCLUSION Intracanalicular dexamethasone 0.4 mg may reduce the medication burden for patients who need prolonged postoperative steroid therapy as is routine in the setting of pterygium surgery. It is a safe and effective alternative to PA 1% drops alone for postoperative control of pain and inflammation in pterygium surgery.
Collapse
Affiliation(s)
- Michelle K. Rhee
- Department of Ophthalmology (M.K.R., J.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Elmhurst Hospital (M.K.R.), Mount Sinai Services, New York, NY; Department of Ophthalmology (M.Z.), New York Eye and Ear Infirmary of Mount Sinai, New York, NY; Lewis Katz School of Medicine at Temple University (M.N.), Philadelphia, PA; Moadel Medicine (H.A., K.M.), New York, NY; and Ektropia Solutions LLC (R.G.), Laguna Beach, CA
| | - Meena Zakher
- Department of Ophthalmology (M.K.R., J.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Elmhurst Hospital (M.K.R.), Mount Sinai Services, New York, NY; Department of Ophthalmology (M.Z.), New York Eye and Ear Infirmary of Mount Sinai, New York, NY; Lewis Katz School of Medicine at Temple University (M.N.), Philadelphia, PA; Moadel Medicine (H.A., K.M.), New York, NY; and Ektropia Solutions LLC (R.G.), Laguna Beach, CA
| | - Michael Najac
- Department of Ophthalmology (M.K.R., J.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Elmhurst Hospital (M.K.R.), Mount Sinai Services, New York, NY; Department of Ophthalmology (M.Z.), New York Eye and Ear Infirmary of Mount Sinai, New York, NY; Lewis Katz School of Medicine at Temple University (M.N.), Philadelphia, PA; Moadel Medicine (H.A., K.M.), New York, NY; and Ektropia Solutions LLC (R.G.), Laguna Beach, CA
| | - Harold Arias
- Department of Ophthalmology (M.K.R., J.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Elmhurst Hospital (M.K.R.), Mount Sinai Services, New York, NY; Department of Ophthalmology (M.Z.), New York Eye and Ear Infirmary of Mount Sinai, New York, NY; Lewis Katz School of Medicine at Temple University (M.N.), Philadelphia, PA; Moadel Medicine (H.A., K.M.), New York, NY; and Ektropia Solutions LLC (R.G.), Laguna Beach, CA
| | - Jace Jo
- Department of Ophthalmology (M.K.R., J.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Elmhurst Hospital (M.K.R.), Mount Sinai Services, New York, NY; Department of Ophthalmology (M.Z.), New York Eye and Ear Infirmary of Mount Sinai, New York, NY; Lewis Katz School of Medicine at Temple University (M.N.), Philadelphia, PA; Moadel Medicine (H.A., K.M.), New York, NY; and Ektropia Solutions LLC (R.G.), Laguna Beach, CA
| | - Richard Gorham
- Department of Ophthalmology (M.K.R., J.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Elmhurst Hospital (M.K.R.), Mount Sinai Services, New York, NY; Department of Ophthalmology (M.Z.), New York Eye and Ear Infirmary of Mount Sinai, New York, NY; Lewis Katz School of Medicine at Temple University (M.N.), Philadelphia, PA; Moadel Medicine (H.A., K.M.), New York, NY; and Ektropia Solutions LLC (R.G.), Laguna Beach, CA
| | - Ken Moadel
- Department of Ophthalmology (M.K.R., J.J.), Icahn School of Medicine at Mount Sinai, New York, NY; Elmhurst Hospital (M.K.R.), Mount Sinai Services, New York, NY; Department of Ophthalmology (M.Z.), New York Eye and Ear Infirmary of Mount Sinai, New York, NY; Lewis Katz School of Medicine at Temple University (M.N.), Philadelphia, PA; Moadel Medicine (H.A., K.M.), New York, NY; and Ektropia Solutions LLC (R.G.), Laguna Beach, CA
| |
Collapse
|
3
|
Hosseini K, Gollamudi S, Reiser H, Walters T, Lindstrom RL. 0.2% Betamethasone Sodium Phosphate: A Multicenter, Randomized, Double-Masked Study to Compare Its Ocular Safety, Tolerability, and Efficacy to Vehicle in Cataract Surgery Subjects. Clin Ophthalmol 2023; 17:2219-2230. [PMID: 37564159 PMCID: PMC10411451 DOI: 10.2147/opth.s419857] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2023] [Accepted: 07/25/2023] [Indexed: 08/12/2023] Open
Abstract
Purpose To compare the preservative-free corticosteroid 0.2% betamethasone sodium phosphate BID (SURF-201) to vehicle BID in patients undergoing routine cataract surgery. Methods Phase 2, multicenter, randomized (1:1 ratio), double-masked, vehicle-controlled, parallel-group study in patients scheduled for uncomplicated cataract surgery without the aid of a femtosecond laser. Subjects instilled topical medications for 16 days beginning the day before cataract surgery (Day -1), 1 dose administered at least 1 hour prior to cataract surgery (on Day 0) and 1 dose on the evening after cataract surgery, and then 2 doses administered each day through Day 15; patients were re-evaluated on Days 22 and 32 to ensure no rebound inflammation. Primary outcome was the difference in the proportion of subjects with anterior chamber cell (ACC) grade 0 between the two groups at Day 15. Secondary outcomes included pain scores and overall safety. Results There was a statistically significant difference (P=0.004) in the proportion of subjects in the SURF-201 treatment group with an ACC grade of 0 at Day 15 (n=22/39 [56.4%]) compared to subjects in the vehicle treatment group (n=9/43 [20.9%]). There was no statistically significant difference (P=0.528) in the proportion of subjects in the SURF-201 treatment group who had a visual analog scale pain score of 0 at Day 15 (n=35/38 [89.7%]) compared to subjects in the vehicle group (n=33/40 [82.5%]). A slightly higher incidence of adverse events occurred in subjects in the SURF-201 treatment group (n=27/40 [67.5%]) compared to the vehicle treatment group (n=23/43 [53.5%]). Conclusion SURF-201 is an effective topical, preservative-free corticosteroid when dosed BID for the treatment of postoperative inflammation and prevention of pain in a post-cataract population.
Collapse
Affiliation(s)
| | | | | | - Tom Walters
- Texan Eye, PA — Keystone Research, Austin, TX, USA
| | | |
Collapse
|